Grifols divests its hemostasis technology business for USD 25 million

Barcelona, October 6, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a leading global healthcare company with a more than 110-year track record contributing to the health
and well-being of people, and an industry forerunner in plasma-derived medicines, transfusion diagnostics and hospital pharmacy solutions, has agreed to sell its hemostasis business for approximately USD 25 million in cash as part of its previously announced divestment process of non-strategic assets.

The transaction comprises all assets related to the diagnosis of hemostasis disorders, including the tests (reagents) and their associated intellectual property, R&D projects and manufacturing know-how, and the instruments (analyzers) used to automate diagnostic coagulation tests. The divestment also includes all Grifols’ hemostasis-related R&D and manufacturing equipment. A workforce of 25 employees has been transferred to the new entity as well.

This product portfolio, known for its high reliability and efficiency, had been marketed by an external distributor since 2018.

The transaction is effective October 1, 2021.

Grifols will continue to evaluate its product portfolio and prioritize growth and profitability in alignment with its long-term value creation strategy.

The company retained Osborne Clarke, S.L.P. as legal advisors for this transaction.